Rapid weight loss can increase gallstone formation, and hospitalists have reported more cases of biliary colic and ...

LISLE, IL, UNITED STATES, January 12, 2026 /EINPresswire.com/ -- OWP Pharmaceuticals today announced commercial product ...

Remote monitoring is increasing as new reimbursement paths open up. But even the best programs are no guarantee of success.

ISTURISA® (osilodrostat) is indicated for the treatment of adult patients with Cushing’s disease who have persistent or recurrent hypercortisolism after primary pituitary surgery and/or ...

A new Cedars Sinai Physician Associated Study used the processes and care of Daybreak to evaluate a dentist-led, ...

February 2026 for ulixacaltamide in essential tremor and relutrigine in SCN2A/8A-DEEs, both with Breakthrough Therapy ...

ESTEVE and TerSera Therapeutics LLC announced today that they have entered into an agreement in which ESTEVE will acquire ...

PLYMOUTH MEETING, Pa.-- (BUSINESS WIRE)--January 12, 2026-- ...

Ascletis Pharma has received investigational new drug (IND) clearance from the US Food and Drug Administration (FDA) to begin ...

MetaVia has shared an update on its attempt to crash the obesity party, reporting average weight loss of 9.1% in people who ...

The KaiNETIC global Phase 3 clinical program includes three global, double-blind, randomized, placebo-controlled Phase 3 trials (KaiNETIC-1, KaiNETIC-2, and KaiNETIC-3) to evaluate weekly ribupatide ...

"MetaVia OXM analogue agonist meets endpoints in Phase Ib weight loss trial" was originally created and published by Clinical ...